Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 23
Filtrer
1.
Malar J ; 21(1): 306, 2022 Oct 28.
Article de Anglais | MEDLINE | ID: mdl-36307852

RÉSUMÉ

BACKGROUND: Resistance to anti-malarial drugs is associated with polymorphisms in target genes and surveillance for these molecular markers is important to detect the emergence of mutations associated with drug resistance and signal recovering sensitivity to anti-malarials previously used. METHODS: The presence of polymorphisms in genes associated with Plasmodium falciparum resistance to chloroquine and sulfadoxine-pyrimethamine was evaluated by Sanger sequencing, in 85 P. falciparum day of enrollment samples from a therapeutic efficacy study of artemether-lumefantrine conducted in 2018-2019 in Quibdo, Colombia. Samples were genotyped to assess mutations in pfcrt (codons 72-76), pfdhfr (codons 51, 59, 108, and 164), and pfdhps genes (codons 436, 437, 540, and 581). Further, the genetic diversity of infections using seven neutral microsatellites (NMSs) (C2M34, C3M69, Poly α, TA1, TA109, 2490, and PfPK2) was assessed. RESULTS: All isolates carried mutant alleles for pfcrt (K76T and N75E), and for pfdhfr (N51I and S108N), while for pfdhps, mutations were observed only for codon A437G (32/73, 43.8%). Fifty samples (58.8%) showed a complete neutral microsatellites (NMS) profile. The low mean number of alleles (2 ± 0.57) per locus and mean expected heterozygosity (0.17 ± 0.03) showed a reduced genetic diversity. NMS multilocus genotypes (MMG) were built and nine MMG were identified. CONCLUSIONS: Overall, these findings confirm the fixation of chloroquine and pyrimethamine-resistant alleles already described in the literature, implying that these drugs are not currently appropriate for use in Colombia. In contrast, mutations in the pfdhps gene were only observed at codon 437, an indication that full resistance to sulfadoxine has not been achieved in Choco. MMGs found matched the clonal lineage E variant 1 previously reported in northwestern Colombia.


Sujet(s)
Antipaludiques , Paludisme à Plasmodium falciparum , Humains , Sulfadoxine/pharmacologie , Sulfadoxine/usage thérapeutique , Pyriméthamine/pharmacologie , Pyriméthamine/usage thérapeutique , Antipaludiques/pharmacologie , Antipaludiques/usage thérapeutique , Plasmodium falciparum , Chloroquine/pharmacologie , Chloroquine/usage thérapeutique , Colombie , Paludisme à Plasmodium falciparum/épidémiologie , Artéméther/usage thérapeutique , Association d'artéméther et de luméfantrine/usage thérapeutique , Association médicamenteuse , Résistance aux substances/génétique , Polymorphisme génétique , Codon
2.
Sci Rep ; 12(1): 1200, 2022 01 24.
Article de Anglais | MEDLINE | ID: mdl-35075191

RÉSUMÉ

The state of Roraima, in Brazil, has recently seen an increase in the number of reported Plasmodium falciparum infections believed to be imported from neighboring countries. The objective of this study was to determine the prevalence of Plasmodium species among patients attending malaria health posts in Roraima and quantify the infections attributable to imported malaria. This cross-sectional case study was carried out between March 2016 and September 2018. Study participants were recruited as they exited the malaria health post. Information about residence, occupation and travel history was collected using a questionnaire. A dried blood spot was collected and used for malaria diagnosis by PCR. A total of 1222 patients were enrolled. Of the 80% Plasmodium positive samples, 50% were P. falciparum, 34% P. vivax, 8% mixed P. falciparum/P. vivax and 0.2% mixed P. falciparum/P. ovale infections and 8% tested positive for Plasmodium, but the species could not be identified. 80% of the malaria patients likely acquired infections in Venezuela and the remaining 20% acquired in Guyana, Brazil, Suriname and French Guyana. 50% of the study participants reported to be working in a mine. Results from this study support the hypothesis that imported malaria contribute to the bulk of malaria diagnosed in Roraima. These findings are in keeping with previous findings and should be considered when developing malaria control interventions.


Sujet(s)
Émigration et immigration , Paludisme/épidémiologie , Plasmodium/isolement et purification , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Brésil/épidémiologie , Enfant , Études transversales , Femelle , Humains , Paludisme/microbiologie , Mâle , Adulte d'âge moyen , Venezuela/ethnologie , Jeune adulte
3.
Am J Trop Med Hyg ; 104(5): 1811-1813, 2021 03 29.
Article de Anglais | MEDLINE | ID: mdl-33782210

RÉSUMÉ

In November 2018, we diagnosed a cluster of falciparum malaria cases in three Chilean travelers returning from Nigeria. Two patients were treated with sequential intravenous artesunate plus oral atovaquone/proguanil (AP) and one with oral AP. The third patient, a 23-year-old man, presented with fever on day 29 after oral AP treatment and was diagnosed with recrudescent falciparum malaria. The patient was then treated with oral mefloquine, followed by clinical recovery and resolution of parasitemia. Analysis of day 0 and follow-up blood samples, collected on days 9, 29, 34, 64, and 83, revealed that parasitemia had initially decreased but then increased on day 29. Sequencing confirmed Tyr268Cys mutation in the cytochrome b gene, associated with atovaquone resistance, in isolates collected on days 29 and 34 and P. falciparum dihydrofolate reductase mutation Asn51Ile, associated with proguanil resistance in all successfully sequenced samples. Molecular characterization of imported malaria contributes to clinical management in non-endemic countries, helps ascertain the appropriateness of antimalarial treatment policies, and contributes to the reporting of drug resistance patterns from endemic regions.


Sujet(s)
Antipaludiques/usage thérapeutique , Résistance aux substances/génétique , Paludisme à Plasmodium falciparum/traitement médicamenteux , Parasitémie/traitement médicamenteux , Plasmodium falciparum/génétique , Protéines de protozoaire/génétique , Adulte , Artésunate/usage thérapeutique , Atovaquone/usage thérapeutique , Chili , Cytochromes b/génétique , Association médicamenteuse , Femelle , Expression des gènes , Humains , Paludisme à Plasmodium falciparum/diagnostic , Paludisme à Plasmodium falciparum/parasitologie , Paludisme à Plasmodium falciparum/anatomopathologie , Mâle , Méfloquine/usage thérapeutique , Mutation , Nigeria , Parasitémie/diagnostic , Parasitémie/parasitologie , Parasitémie/anatomopathologie , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/croissance et développement , Plasmodium falciparum/pathogénicité , Proguanil/usage thérapeutique , Récidive , Dihydrofolate reductase/génétique , Voyage
4.
Malar J ; 19(1): 379, 2020 Oct 23.
Article de Anglais | MEDLINE | ID: mdl-33097045

RÉSUMÉ

BACKGROUND: With increasing interest in eliminating malaria from the Caribbean region, Haiti is one of the two countries on the island of Hispaniola with continued malaria transmission. While the Haitian population remains at risk for malaria, there are a limited number of cases annually, making conventional epidemiological measures such as case incidence and prevalence of potentially limited value for fine-scale resolution of transmission patterns and trends. In this context, genetic signatures may be useful for the identification and characterization of the Plasmodium falciparum parasite population in order to identify foci of transmission, detect outbreaks, and track parasite movement to potentially inform malaria control and elimination strategies. METHODS: This study evaluated the genetic signals based on analysis of 21 single-nucleotide polymorphisms (SNPs) from 462 monogenomic (single-genome) P. falciparum DNA samples extracted from dried blood spots collected from malaria-positive patients reporting to health facilities in three southwestern Haitian departments (Nippes, Grand'Anse, and Sud) in 2016. RESULTS: Assessment of the parasite genetic relatedness revealed evidence of clonal expansion within Nippes and the exchange of parasite lineages between Nippes, Sud, and Grand'Anse. Furthermore, 437 of the 462 samples shared high levels of genetic similarity-at least 20 of 21 SNPS-with at least one other sample in the dataset. CONCLUSIONS: These results revealed patterns of relatedness suggestive of the repeated recombination of a limited number of founding parasite types without significant outcrossing. These genetic signals offer clues to the underlying relatedness of parasite populations and may be useful for the identification of the foci of transmission and tracking of parasite movement in Haiti for malaria elimination.


Sujet(s)
ADN des protozoaires/analyse , Plasmodium falciparum/génétique , Polymorphisme de nucléotide simple , Haïti
5.
Malar J ; 19(1): 289, 2020 Aug 13.
Article de Anglais | MEDLINE | ID: mdl-32792011

RÉSUMÉ

BACKGROUND: Chile is one of the South American countries certified as malaria-free since 1945. However, the recent increase of imported malaria cases and the presence of the vector Anopheles pseudopunctipennis in previously endemic areas in Chile require an active malaria surveillance programme. METHODS: Specimens from 268 suspected malaria cases-all imported-collected between 2015 and 2018 at the Public Health Institute of Chile (ISP), were diagnosed by microscopy and positive cases were included for epidemiological analysis. A photo-induced electron transfer fluorogenic primer real-time PCR (PET-PCR) was used to confirm the presence of malaria parasites in available blood samples. Sanger sequencing of drug resistance molecular markers (pfk13, pfcrt and pfmdr1) and microsatellite (MS) analysis were performed in confirmed Plasmodium falciparum samples and results were related to origin of infection. RESULTS: Out of the 268 suspected cases, 65 were Plasmodium spp. positive by microscopy. A total of 63% of the malaria patients were male and 37% were female; 43/65 of the patients acquired infections in South American endemic countries. Species confirmation of available blood samples by PET-PCR revealed that 15 samples were positive for P. falciparum, 27 for Plasmodium vivax and 4 were mixed infections. The P. falciparum samples sequenced contained four mutant pfcrt genotypes (CVMNT, CVMET, CVIET and SVMNT) and three mutant pfmdr1 genotypes (Y184F/S1034C/N1042D/D1246Y, Y184F/N1042D/D1246Y and Y184F). MS analysis confirmed that all P. falciparum samples presented different haplotypes according to the suspected country of origin. Four patients with P. vivax infection returned to the health facilities due to relapses. CONCLUSION: The timely detection of polymorphisms associated with drug resistance will contribute to understanding if current drug policies in the country are appropriate for treatment of imported malaria cases and provide information about the most frequent resistant genotypes entering Chile.


Sujet(s)
Co-infection/épidémiologie , Maladies transmissibles importées/épidémiologie , Paludisme à Plasmodium falciparum/épidémiologie , Paludisme à Plasmodium vivax/épidémiologie , Plasmodium falciparum/physiologie , Plasmodium vivax/physiologie , Adolescent , Adulte , Sujet âgé , Enfant , Enfant d'âge préscolaire , Chili/épidémiologie , Co-infection/parasitologie , Co-infection/transmission , Maladies transmissibles importées/parasitologie , Maladies transmissibles importées/transmission , Résistance aux substances/génétique , Femelle , Humains , Paludisme à Plasmodium falciparum/parasitologie , Paludisme à Plasmodium falciparum/transmission , Paludisme à Plasmodium vivax/parasitologie , Paludisme à Plasmodium vivax/transmission , Mâle , Adulte d'âge moyen , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/génétique , Plasmodium vivax/effets des médicaments et des substances chimiques , Plasmodium vivax/génétique , Jeune adulte
6.
PLoS One ; 15(6): e0234263, 2020.
Article de Anglais | MEDLINE | ID: mdl-32525900

RÉSUMÉ

The current context of malaria elimination requires urgent development and implementation of highly sensitive and specific methods for prompt detection and treatment of malaria parasites. Such methods should overcome current delays in diagnosis, allow the detection of low-density infections and address the difficulties in accessing remote endemic communities. In this study, we assessed the performance of the RealAmp and malachite-green loop mediated isothermal amplification (MG-LAMP) methodologies, using microscopy and conventional nested-PCR as reference techniques. Both LAMP techniques were performed for Plasmodium genus, P. falciparum, and P. vivax identification using 136 whole blood samples collected from three communities located in the Peruvian Amazon basin. Turnaround time and costs of performing the LAMP assays were estimated and compared to that of microscopy and nested-PCR. Using nested-PCR as reference standard, we calculated the sensitivity, specificity and 95% confidence interval (CI) for all methods. RealAmp had a sensitivity of 92% (95% CI: 85-96.5%) and specificity of 100% (95% CI: 89.1-100%) for species detection; sensitivity and specificity of MG-LAMP were 94% (95% CI: 87.5-97.8%) and 100% (89.1-100%), respectively. Whereas microscopy showed 88.1% sensitivity (95% CI: 80.2-93.7%) and 100% specificity (95%: 89.1-100%). The turnaround time and costs of performing the LAMP assays were lower compared to those associated with nested-PCR but higher than those associated with microscopy. The two LAMP assays were shown to be more sensitive and simple to implement than microscopy. Both LAMP methodologies could be used as large-scale screening tests, but the MG-LAMP assay uses a simple, portable heat-block while the RealAmp requires a RealAmp machine or a real-time PCR machine. This makes the MG-LAMP an appropriate choice for malaria surveillance studies in endemic sites. Use of LAMP tests in active case detection of Plasmodium parasites could help to detect positive malaria cases early.


Sujet(s)
Techniques d'amplification d'acides nucléiques/méthodes , Composés organométalliques/métabolisme , Plasmodium falciparum/génétique , Plasmodium falciparum/isolement et purification , Plasmodium vivax/génétique , Plasmodium vivax/isolement et purification , Température , Adulte , Femelle , Humains , Limite de détection , Paludisme à Plasmodium falciparum/diagnostic , Paludisme à Plasmodium vivax/diagnostic , Mâle , Plasmodium falciparum/physiologie , Plasmodium vivax/physiologie , Facteurs temps
7.
Elife ; 92020 05 12.
Article de Anglais | MEDLINE | ID: mdl-32394893

RÉSUMÉ

Antimalarial drug resistance has historically arisen through convergent de novo mutations in Plasmodium falciparum parasite populations in Southeast Asia and South America. For the past decade in Southeast Asia, artemisinins, the core component of first-line antimalarial therapies, have experienced delayed parasite clearance associated with several pfk13 mutations, primarily C580Y. We report that mutant pfk13 has emerged independently in Guyana, with genome analysis indicating an evolutionary origin distinct from Southeast Asia. Pfk13 C580Y parasites were observed in 1.6% (14/854) of samples collected in Guyana in 2016-2017. Introducing pfk13 C580Y or R539T mutations by gene editing into local parasites conferred high levels of in vitro artemisinin resistance. In vitro growth competition assays revealed a fitness cost associated with these pfk13 variants, potentially explaining why these resistance alleles have not increased in frequency more quickly in South America. These data place local malaria control efforts at risk in the Guiana Shield.


All recommended treatments against malaria include a drug called artemisinin or some of its derivatives. However, there are concerns that Plasmodium falciparum, the parasite that causes most cases of malaria, will eventually develop widespread resistance to the drug. A strain of P. falciparum partially resistant to artemisinin was seen in Cambodia in 2008, and it has since spread across Southeast Asia. The resistance appears to be frequently linked to a mutation known as pfk13 C580Y. Southeast Asia and Amazonia are considered to be hotspots for antimalarial drug resistance, and the pfk13 C580Y mutation was detected in the South American country of Guyana in 2010. To examine whether the mutation was still circulating in this part of the world, Mathieu et al. collected and analyzed 854 samples across Guyana between 2016 and 2017. Overall, 1.6% of the samples had the pfk13 C580Y mutation, but this number was as high as 8.8% in one region. Further analyses revealed that the mutation in Guyana had not spread from Southeast Asia, but that it had occurred in Amazonia independently. To better understand the impact of the pfk13 C580Y mutation, Mathieu et al. introduced this genetic change into non-resistant parasites from a country neighbouring Guyana. As expected, the mutation made P. falciparum highly resistant to artemisinin, but it also slowed the growth rate of the parasite. This disadvantage may explain why the mutation has not spread more rapidly through Guyana in recent years. Artemisinin and its derivatives are always associated with other antimalarial drugs to slow the development of resistance; there are concerns that reduced susceptibility to artemisinin leads to the parasites becoming resistant to the partner drugs. Further research is needed to evaluate how the pfk13 C580Y mutation affects the parasite's response to the typical combination of drugs that are given to patients.


Sujet(s)
Antipaludiques/pharmacologie , Artémisinines/pharmacologie , Paludisme à Plasmodium falciparum/parasitologie , Plasmodium falciparum/génétique , Protéines de protozoaire/génétique , Antipaludiques/usage thérapeutique , Artémisinines/usage thérapeutique , Résistance aux substances/génétique , Gènes de protozoaire , Aptitude génétique , Guyana/épidémiologie , Haplotypes , Humains , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/épidémiologie , Mutation , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/croissance et développement , Séquençage du génome entier
8.
Sci Rep ; 10(1): 3756, 2020 02 28.
Article de Anglais | MEDLINE | ID: mdl-32111872

RÉSUMÉ

As malaria control programmes concentrate their efforts towards malaria elimination a better understanding of malaria transmission patterns at fine spatial resolution units becomes necessary. Defining spatial units that consider transmission heterogeneity, human movement and migration will help to set up achievable malaria elimination milestones and guide the creation of efficient operational administrative control units. Using a combination of genetic and epidemiological data we defined a malaria transmission unit as the area contributing 95% of malaria cases diagnosed at the catchment facility located in the town of Guapi in the South Pacific Coast of Colombia. We provide data showing that P. falciparum malaria transmission is heterogeneous in time and space and analysed, using topological data analysis, the spatial connectivity, at the micro epidemiological level, between parasite populations circulating within the unit. To illustrate the necessity to evaluate the efficacy of malaria control measures within the transmission unit in order to increase the efficiency of the malaria control effort, we provide information on the size of the asymptomatic reservoir, the nature of parasite genotypes associated with drug resistance as well as the frequency of the Pfhrp2/3 deletion associated with false negatives when using Rapid Diagnostic Tests.


Sujet(s)
Antigènes de protozoaire/génétique , Résistance aux substances/génétique , Délétion de gène , Paludisme à Plasmodium falciparum , Plasmodium falciparum , Protéines de protozoaire/génétique , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Colombie/épidémiologie , Femelle , Humains , Nourrisson , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/épidémiologie , Paludisme à Plasmodium falciparum/génétique , Paludisme à Plasmodium falciparum/transmission , Mâle , Adulte d'âge moyen , Plasmodium falciparum/génétique , Plasmodium falciparum/pathogénicité
9.
Am J Trop Med Hyg ; 102(5): 1056-1063, 2020 05.
Article de Anglais | MEDLINE | ID: mdl-32100686

RÉSUMÉ

Artemether-lumefantrine (AL) is the first-line treatment for uncomplicated Plasmodium falciparum infection in Colombia. To assess AL efficacy for uncomplicated falciparum malaria in Quibdo, Choco, Colombia, we conducted a 28-day therapeutic efficacy study (TES) following the WHO guidelines. From July 2018 to February 2019, febrile patients aged 5-65 years with microscopy-confirmed P. falciparum mono-infection and asexual parasite density of 250-100,000 parasites/µL were enrolled and treated with a supervised 3-day course of AL. The primary endpoint was adequate clinical and parasitological response (ACPR) on day 28. We attempted to use polymerase chain reaction (PCR) genotyping to differentiate reinfection and recrudescence, and conducted genetic testing for antimalarial resistance-associated genes. Eighty-eight patients consented and were enrolled; four were lost to follow-up or missed treatment doses. Therefore, 84 (95.5%) participants reached a valid endpoint: treatment failure or ACPR. No patient remained microscopy positive for malaria on day 3, evidence of delayed parasite clearance and artemisinin resistance. One patient had recurrent infection (12 parasites/µL) on day 28. Uncorrected ACPR rate was 98.8% (83/84) (95% CI: 93.5-100%). The recurrent infection sample did not amplify during molecular testing, giving a PCR-corrected ACPR of 100% (83/83) (95% CI: 95.7-100%). No P. falciparum kelch 13 polymorphisms associated with artemisinin resistance were identified. Our results support high AL efficacy for falciparum malaria in Choco. Because of the time required to conduct TESs in low-endemic settings, it is important to consider complementary alternatives to monitor antimalarial efficacy and resistance.


Sujet(s)
Antipaludiques/usage thérapeutique , Association d'artéméther et de luméfantrine/usage thérapeutique , Paludisme à Plasmodium falciparum/traitement médicamenteux , Adolescent , Adulte , Facteurs âges , Sujet âgé , Antipaludiques/administration et posologie , Association d'artéméther et de luméfantrine/administration et posologie , Enfant , Enfant d'âge préscolaire , Colombie , Résistance aux substances/génétique , Femelle , Humains , Mâle , Adulte d'âge moyen , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/génétique , Polymorphisme de nucléotide simple/génétique , Résultat thérapeutique , Jeune adulte
10.
Am J Trop Med Hyg ; 102(2): 310-312, 2020 02.
Article de Anglais | MEDLINE | ID: mdl-31833470

RÉSUMÉ

Given that the C580Y polymorphism in the Plasmodium falciparum propeller domain of the kelch 13 gene (pfk13) was documented in Guyana, monitoring for mutations associated with antimalarial resistance was undertaken in neighboring Roraima state in Brazil. Polymorphisms in the pfmdr1 and pfk13 genes were investigated in 275 P. falciparum samples. No pfk13 mutations were observed. Triple mutants 184F, 1042D, and 1246Y were observed in 100% of the samples successfully sequenced for the pfmdr1 gene, with 20.1% of these having an additional mutation at codon 1034C. Among them, 2.5% of samples harbored two copies of the pfmdr1 gene. We found no evidence of the spread of C580Y parasites to Roraima state, Brazil. As previously observed, the 184F, 1042D, and 1246Y mutations in the pfmdr1 gene appear to be fixed in this region. Continued molecular surveillance is essential to detect any potential migration or local emergence of artemisinin-resistant mutation.


Sujet(s)
Artémisinines/administration et posologie , Artémisinines/pharmacologie , Résistance aux substances/génétique , Paludisme à Plasmodium falciparum/parasitologie , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/génétique , Transporteurs ABC/génétique , Brésil/épidémiologie , Humains , Paludisme à Plasmodium falciparum/traitement médicamenteux , Paludisme à Plasmodium falciparum/épidémiologie , Polymorphisme génétique , Protéines de protozoaire/génétique
11.
Malar J ; 18(1): 98, 2019 Mar 25.
Article de Anglais | MEDLINE | ID: mdl-30909912

RÉSUMÉ

BACKGROUND: Microscopic detection of malaria parasites is the standard method for clinical diagnosis of malaria in Brazil. However, malaria epidemiological surveillance studies specifically aimed at the detection of low-density infection and asymptomatic cases will require more sensitive and field-usable tools. The diagnostic accuracy of the colorimetric malachite green, loop-mediated, isothermal amplification (MG-LAMP) assay was evaluated in remote health posts in Roraima state, Brazil. METHODS: Study participants were prospectively enrolled from health posts (healthcare-seeking patients) and from nearby villages (healthy participants) in three different study sites. The MG-LAMP assay and microscopy were performed in the health posts. Two independent readers scored the MG-LAMP tests as positive (blue/green) or negative (clear). Sensitivity and specificity of local microscopy and MG-LAMP were calculated using results of PET-PCR as a reference. RESULTS: A total of 91 participants were enrolled. There was 100% agreement between the two MG-LAMP readers (Kappa = 1). The overall sensitivity and specificity of MG-LAMP were 90.0% (95% confidence interval (CI) 76.34-97.21%) and 94% (95% CI 83.76-98.77%), respectively. The sensitivity and specificity of local microscopy were 83% (95% CI 67.22-92.66%) and 100% (95% CI 93.02-100.00%), respectively. PET-PCR detected six mixed infections (infection with both Plasmodium falciparum and Plasmodium vivax); two of these were also detected by MG-LAMP and one by microscopy. Microscopy did not detect any Plasmodium infection in the 26 healthy participants; MG-LAMP detected Plasmodium in five of these and PET-PCR assay detected infection in three. Overall, performing the MG-LAMP in this setting did not present any particular challenges. CONCLUSION: MG-LAMP is a sensitive and specific assay that may be useful for the detection of malaria parasites in remote healthcare settings. These findings suggest that it is possible to implement simple molecular tests in facilities with limited resources.


Sujet(s)
Paludisme à Plasmodium falciparum/diagnostic , Paludisme à Plasmodium vivax/diagnostic , Techniques d'amplification d'acides nucléiques/méthodes , Plasmodium falciparum/isolement et purification , Plasmodium vivax/isolement et purification , Surveillance de la population/méthodes , Magenta I/composition chimique , Brésil , Humains , Techniques d'amplification d'acides nucléiques/instrumentation , Sensibilité et spécificité
12.
PLoS One ; 13(7): e0200492, 2018.
Article de Anglais | MEDLINE | ID: mdl-29995953

RÉSUMÉ

Conventional molecular methods, such as nested polymerase chain reaction (PCR), are very sensitive for detection of malaria parasites, but require advanced laboratory equipment and trained personnel. Real-time loop-mediated isothermal amplification (RealAmp), a loop-mediated isothermal amplification-based molecular tool (LAMP), facilitates rapid target amplification at a single temperature setting, reducing the need for sophisticated equipment. We evaluated the performance of a field-adapted RealAmp assay for malaria diagnosis in Cruzeiro do Sul, Acre State, Brazil, a remote area in Brazil with limited laboratory capabilities. We enrolled 1,000 patients with fever (axillary temperature ≥ 37.5 C) or history of fever in last 24 h presenting for malaria diagnosis from February through June 2015. DNA was extracted from dried blood spots using a boil and spin method (heat treatment) at the sample processing site, and also using commercial kits at a Brazilian national reference laboratory. RealAmp was performed for Plasmodium genus, P. falciparum, and P. vivax identification. In addition, Giemsa-stained blood smears were prepared and examined by two independent well-trained study microscopists. A combination of Real-time PCR and nested PCR was used as reference test. The sensitivity and specificity of RealAmp in the field site laboratory were 94.1% (95% confidence interval [CI]: 90.1-96.8) and 83.9% (95% CI: 81.1-86.4), respectively. The sensitivity and specificity of local microscopy were 87.7% (95% CI: 82.6-91.7) and 98.9% (95% CI: 97.8-99.4), respectively, while study microscopy showed sensitivity of 96.4% (95% CI: 93.0-98.4) and specificity of 98.2% (95% CI: 97.0-99.0). None of the three tests detected 20 P. falciparum and P. vivax mixed infections identified by the reference test. Our findings highlight that it is possible to implement simple molecular tests in facilities with limited resources such as Cruzeiro do Sul in Brazil. RealAmp sensitivity was similar to that of microscopy performed by skilled professionals; both RealAmp and study microscopy performed poorly in detection of mixed infection. Attempts to develop and evaluate simpler molecular tools should continue, especially for the detection of malaria infection in remote areas.


Sujet(s)
Paludisme à Plasmodium falciparum , Paludisme à Plasmodium vivax , Techniques d'amplification d'acides nucléiques/méthodes , Plasmodium falciparum/génétique , Plasmodium vivax/génétique , Brésil , Femelle , Humains , Paludisme à Plasmodium falciparum/sang , Paludisme à Plasmodium falciparum/diagnostic , Paludisme à Plasmodium falciparum/génétique , Paludisme à Plasmodium vivax/sang , Paludisme à Plasmodium vivax/diagnostic , Paludisme à Plasmodium vivax/génétique , Mâle , Sensibilité et spécificité
13.
Am J Trop Med Hyg ; 98(1): 88-94, 2018 01.
Article de Anglais | MEDLINE | ID: mdl-29141762

RÉSUMÉ

We evaluated the therapeutic efficacy of artemether-lumefantrine (AL) fixed-dose combination to treat uncomplicated Plasmodium falciparum malaria in Cruzeiro do Sul, Acre State, in the Amazon region of Brazil. Between December 2015 and May 2016, we enrolled 79 patients, 5-79 years old with fever or history of fever in the previous 48 hours and P. falciparum monoinfection confirmed by microscopy. Attempts were made to provide direct observation or phone reminders for all six doses of AL, and patients were followed-up for 28 days. AL was well tolerated, with no adverse events causing treatment interruption. All but one of the 74 patients who completed the 28-day follow-up had an adequate clinical and parasitologic response = 98.6% (95% CI: 93.2-100%). We could not amplify the one isolate of the case with recurrent infection to differentiate between recrudescence and reinfection. Five (6.3%) patients demonstrated persistent asexual parasitemia on Day 3, but none met definition for early treatment failure. We found no mutations in selected kelch13 gene domains, known to be associated with artemisinin resistance in P. falciparum isolates from Day 0. These results strongly support the continued use of AL as a first-line therapy for uncomplicated P. falciparum malaria in Acre. Routine monitoring of in vivo drug efficacy coupled with molecular surveillance of drug resistance markers remains critical.


Sujet(s)
Association d'artéméther et de luméfantrine/usage thérapeutique , Paludisme à Plasmodium falciparum/traitement médicamenteux , Plasmodium gallinaceum/effets des médicaments et des substances chimiques , Adolescent , Adulte , Sujet âgé , Brésil/épidémiologie , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Paludisme à Plasmodium falciparum/épidémiologie , Mâle , Adulte d'âge moyen , Résultat thérapeutique , Jeune adulte
14.
Am J Trop Med Hyg ; 97(3): 758-760, 2017 Sep.
Article de Anglais | MEDLINE | ID: mdl-28749761

RÉSUMÉ

The Caribbean island of Hispaniola is targeted for malaria elimination. Currently, this is the only island with ongoing transmission of malaria in the Caribbean. In 2015, six patients from Puerto Rico and one from Massachusetts, who traveled to Punta Cana, Dominican Republic, were confirmed to be infected with Plasmodium falciparum. Additional molecular analysis was performed at the Centers for Disease Control and Prevention to characterize the drug-resistant alleles and Plasmodium population genetic markers. All specimens carried wildtype genotypes for chloroquine, sulfadoxine-pyrimethamine, and artemisinin resistance genetic markers. A mutation in codon 184 (Y/F) of Pfmdr-1 gene was observed in all samples and they shared an identical genetic lineage as determined by microsatellite analysis. This genetic profile was similar to one previously reported from Hispaniola suggesting that a clonal P. falciparum residual parasite population present in Punta Cana is the source population for these imported malaria cases.


Sujet(s)
Paludisme à Plasmodium falciparum/épidémiologie , Paludisme à Plasmodium falciparum/parasitologie , Plasmodium falciparum/génétique , Voyage , Marqueurs génétiques , Humains , Paludisme , Phylogenèse , Plasmodium falciparum/isolement et purification , Porto Rico/épidémiologie
15.
Article de Anglais | MEDLINE | ID: mdl-28438929

RÉSUMÉ

In Suriname, an artesunate monotherapy therapeutic efficacy trial was recently conducted to evaluate partial artemisinin resistance emerging in Plasmodium falciparum We genotyped the PfK13 propeller domain of P. falciparum in 40 samples as well as other mutations proposed to be associated with artemisinin-resistant mutants. We did not find any mutations previously associated with artemisinin resistance in Southeast Asia, but we found fixed resistance mutations for chloroquine (CQ) and sulfadoxine-pyrimethamine. Additionally, the PfCRT C350R mutation, associated with reversal of CQ resistance and piperaquine-selective pressure, was present in 62% of the samples. Our results from neutral microsatellite data also confirmed a high parasite gene flow in the Guiana Shield. Although recruiting participants for therapeutic efficacy studies is challenging in areas where malaria endemicity is very low due to the low number of malaria cases reported, conducting these studies along with molecular surveillance remains essential for the monitoring of artemisinin-resistant alleles and for the characterization of the population structure of P. falciparum in areas targeted for malaria elimination.


Sujet(s)
Antipaludiques/usage thérapeutique , Chloroquine/usage thérapeutique , Protéines de protozoaire/génétique , Artémisinines/usage thérapeutique , Résistance aux substances/génétique , Génotype , Paludisme/traitement médicamenteux , Paludisme/génétique , Mutation/génétique , Plasmodium falciparum , Suriname
16.
PLoS One ; 12(2): e0172139, 2017.
Article de Anglais | MEDLINE | ID: mdl-28192523

RÉSUMÉ

Detection of histidine-rich protein 2 (HRP2) from the malaria parasite Plasmodium falciparum provides evidence for active or recent infection, and is utilized for both diagnostic and surveillance purposes, but current laboratory immunoassays for HRP2 are hindered by low sensitivities and high costs. Here we present a new HRP2 immunoassay based on antigen capture through a bead-based system capable of detecting HRP2 at sub-picogram levels. The assay is highly specific and cost-effective, allowing fast processing and screening of large numbers of samples. We utilized the assay to assess results of HRP2-based rapid diagnostic tests (RDTs) in different P. falciparum transmission settings, generating estimates for true performance in the field. Through this method of external validation, HRP2 RDTs were found to perform well in the high-endemic areas of Mozambique and Angola with 86.4% and 73.9% of persons with HRP2 in their blood testing positive by RDTs, respectively, and false-positive rates of 4.3% and 0.5%. However, in the low-endemic setting of Haiti, only 14.5% of persons found to be HRP2 positive by the bead assay were RDT positive. Additionally, 62.5% of Haitians showing a positive RDT test had no detectable HRP2 by the bead assay, likely indicating that these were false positive tests. In addition to RDT validation, HRP2 biomass was assessed for the populations in these different settings, and may provide an additional metric by which to estimate P. falciparum transmission intensity and measure the impact of interventions.


Sujet(s)
Antigènes de protozoaire/analyse , Dosage immunologique/méthodes , Paludisme à Plasmodium falciparum/diagnostic , Plasmodium falciparum/métabolisme , Protéines de protozoaire/analyse , Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Séquence d'acides aminés , Angola/épidémiologie , Enfant , Enfant d'âge préscolaire , Études transversales , Tests diagnostiques courants/méthodes , Maladies endémiques , Haïti/épidémiologie , Enquêtes de santé/méthodes , Enquêtes de santé/statistiques et données numériques , Interactions hôte-parasite , Humains , Nourrisson , Paludisme à Plasmodium falciparum/épidémiologie , Paludisme à Plasmodium falciparum/parasitologie , Adulte d'âge moyen , Mozambique/épidémiologie , Plasmodium falciparum/génétique , Plasmodium falciparum/physiologie , Protéines de protozoaire/génétique , Reproductibilité des résultats , Sensibilité et spécificité , Jeune adulte
17.
Am J Trop Med Hyg ; 95(4): 811-816, 2016 10 05.
Article de Anglais | MEDLINE | ID: mdl-27430541

RÉSUMÉ

Chloroquine (CQ) remains the first-line treatment of malaria in Haiti. Given the challenges of conducting in vivo drug efficacy trials in low-endemic settings like Haiti, molecular surveillance for drug resistance markers is a reasonable approach for detecting resistant parasites. In this study, 349 blood spots were collected from suspected malaria cases in areas in and around Port-au-Prince from March to July 2010. Among them, 121 samples that were Plasmodium falciparum positive by polymerase chain reaction were genotyped for drug-resistant pfcrt, pfdhfr, pfdhps, and pfmdr1 alleles. Among the 108 samples that were successfully sequenced for CQ resistant markers in pfcrt, 107 were wild type (CVMNK), whereas one sample carried a CQ-resistant allele (CVIET). Neutral microsatellite genotyping revealed that the CQ-resistant isolate was distinct from all other samples in this study. Furthermore, the remaining parasite specimens appeared to be genetically distinct from other reported Central and South American populations.


Sujet(s)
Antipaludiques/pharmacologie , Résistance aux substances/génétique , Paludisme à Plasmodium falciparum/parasitologie , Plasmodium falciparum/génétique , Allèles , Chloroquine/pharmacologie , Association médicamenteuse , Tremblements de terre , Génétique des populations , Haïti/épidémiologie , Haplotypes , Humains , Paludisme à Plasmodium falciparum/épidémiologie , Protéines de transport membranaire/génétique , Répétitions microsatellites/génétique , Protéines associées à la multirésistance aux médicaments/génétique , Mutation , Plasmodium falciparum/classification , Plasmodium falciparum/effets des médicaments et des substances chimiques , Prévalence , Protéines de protozoaire/génétique , Pyriméthamine/pharmacologie , Sulfadoxine/pharmacologie
18.
PLoS One ; 11(3): e0150391, 2016.
Article de Anglais | MEDLINE | ID: mdl-26959994

RÉSUMÉ

BACKGROUND: Efforts have been made to establish sensitive diagnostic tools for malaria screening in blood banks in order to detect malaria asymptomatic carriers. Microscopy, the malaria reference test in Brazil, is time consuming and its sensitivity depends on microscopist experience. Although molecular tools are available, some aspects need to be considered for large-scale screening: accuracy and robustness for detecting low parasitemia, affordability for application to large number of samples and flexibility to perform on individual or pooled samples. METHODOLOGY: In this retrospective study, we evaluated four molecular assays for detection of malaria parasites in a set of 56 samples previously evaluated by expert microscopy. In addition, we evaluated the effect of pooling samples on the sensitivity and specificity of the molecular assays. A well-characterized cultured sample with 1 parasite/µL was included in all the tests evaluated. DNA was extracted with QIAamp DNA Blood Mini Kit and eluted in 50 µL to concentrate the DNA. Pools were assembled with 10 samples each. Molecular protocols targeting 18S rRNA, included one qPCR genus specific (Lima-genus), one duplex qPCR genus/Pf (PET-genus, PET-Pf) and one duplex qPCR specie-specific (Rougemont: Roug-Pf/Pv and Roug-Pm/Po). Additionally a nested PCR protocol specie-specific was used (Snou-Pf, Snou-Pv, Snou-Pm and Snou-Po). RESULTS: The limit of detection was 3.5 p/µL and 0.35p/µl for the PET-genus and Lima-genus assays, respectively. Considering the positive (n = 13) and negative (n = 39) unpooled individual samples according to microscopy, the sensitivity of the two genus qPCR assays was 76.9% (Lima-genus) and 72.7% (PET-genus). The Lima-genus and PET-genus showed both sensitivity of 86.7% in the pooled samples. The genus protocols yielded similar results (Kappa value of 1.000) in both individual and pooled samples. CONCLUSIONS: Efforts should be made to improve performance of molecular tests to enable the detection of low-density parasitemia if these tests are to be utilized for blood transfusion screening.


Sujet(s)
Tests diagnostiques courants/tendances , Paludisme/diagnostic , Brésil , ADN des protozoaires/génétique , Sélection de donneurs , Humains , Réaction de polymérisation en chaîne , Réaction de polymérisation en chaine en temps réel , Études rétrospectives , Sensibilité et spécificité
19.
J Infect Dis ; 213(9): 1472-5, 2016 May 01.
Article de Anglais | MEDLINE | ID: mdl-26690347

RÉSUMÉ

Suspected artemisinin resistance in Plasmodium falciparum can be explored by examining polymorphisms in the Kelch (PfK13) propeller domain. Sequencing of PfK13 and other gene resistance markers was performed on 98 samples from Guyana. Five of these samples carried the C580Y allele in the PfK13 propeller domain, with flanking microsatellite profiles different from those observed in Southeast Asia. These molecular data demonstrate independent emergence of the C580Y K13 mutant allele in Guyana, where resistance alleles to previously used drugs are fixed. Therefore, in Guyana and neighboring countries, continued molecular surveillance and periodic assessment of the therapeutic efficacy of artemisinin-based combination therapy are warranted.


Sujet(s)
Résistance aux substances/génétique , Paludisme à Plasmodium falciparum/parasitologie , Plasmodium falciparum/effets des médicaments et des substances chimiques , Plasmodium falciparum/génétique , Antipaludiques/pharmacologie , Artémisinines/pharmacologie , ADN des protozoaires/analyse , ADN des protozoaires/génétique , Association de médicaments , Guyana/épidémiologie , Humains , Paludisme à Plasmodium falciparum/épidémiologie , Typage moléculaire , Mutation/génétique
20.
Malar J ; 13 Suppl 1: 497, 2015 Dec 10.
Article de Anglais | MEDLINE | ID: mdl-26651993

RÉSUMÉ

BACKGROUND: Determining the source of malaria outbreaks in Ecuador and identifying remaining transmission foci will help in malaria elimination efforts. In this study, the genetic signatures of Plasmodium falciparum isolates, obtained from an outbreak that occurred in northwest Ecuador from 2012 to 2013, were characterized. METHODS: Molecular investigation of the outbreak was performed using neutral microsatellites, drug resistance markers and pfhrp2 and pfhrp3 genotyping. RESULTS: A majority of parasite isolates (31/32) from this outbreak were of a single clonal type that matched a clonal lineage previously described on the northern coast of Peru and a historical isolate from Ecuador. All but one isolate carried a chloroquine-resistant pfcrt genotype and sulfadoxine- and pyrimethamine-sensitive pfdhps and pfdhfr genotypes. Pfmdr1 mutations were identified in codons 184 and 1042. In addition, most samples (97 %) showed presence of pfhrp2 gene. CONCLUSIONS: This study indicates that parasites from a single clonal lineage largely contributed to this outbreak and this lineage was found to be genetically related to a lineage previously reported in the Peruvian coast and historical Ecuadorian parasites.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE